View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource® (PER®), LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps
for Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies focuses on areas of clinical challenge faced by practicing oncologists, along with emerging therapeutic approaches being developed to tackle these challenges.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios.


Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies

Release Date: March 31, 2017
Expiration Date: March 31, 2018
Media: Internet - based

 

Activity Overview

This activity focuses on emerging therapies for acute myeloid leukemia (AML). It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in January 2017 at New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies, a series of live symposia that were held adjunct to the Highlights of ASH® in North America conferences in Seattle. In their interviews, Program Chair Eytan Stein, MD, and the faculty, Daniel J. DeAngelo, MD, PhD; and Harry Erba, MD, PhD, review and share perspectives on current standards of care, the clinical implication of new data, and advances of novel therapeutic strategies.

CME/CE Activity Table of Contents

  • The Biology of AML and Its Therapeutic Implications
    Daniel DeAngelo, MD, PhD
  • Assessing Potential Therapeutic Targets in AML
    Harry Erba, MD, PhD
  • Current and Emerging Roles for Multikinase Inhibitors in Patients With Activating FLT3 Mutations
    Daniel DeAngelo, MD, PhD
  • IDH Inhibitors: A Look at Evolving Data Sets and Ongoing Clinical Trials
    Eytan Stein, MD
  • Methods to Optimize Outcomes in Older Adults With AML
    Harry Erba, MD, PhD
  • A Look at the Near Future: Rationale Drug Combinations With Targeted Agents in AML
    Eytan Stein, MD
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is intended for medical oncologists, hematologists, nurses, physician assistants, fellows and other healthcare professionals interested in emerging data and advances in treatment of AML.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Determine contemporary strategies for the management of AML and clinically unmet needs in the field
  • Discuss activating mutations identified in AML that provide the rationale for the development of targeted mechanistic approaches
  • Explain recent clinical trial results concerning novel targeted strategies to manage AML and next steps in the field with single agent and combination trials
  • Place recent clinical trial findings on targeted strategies in the context of evolving treatment paradigms and how targeted approaches may be used to optimize outcomes in AML

Faculty, Staff, and Planners' Disclosures

Faculty

Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Physician, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Amgen, Bristol-Myers Squibb, Ariad, Incyte, Pfizer, Novartis, Celgene

Harry Erba, MD, PhD
Professor of Medicine
Director of the UAB Hematologic Malignancy Program
Associate Director for Clinical Research
The University of Alabama Comprehensive Cancer Center
Birmingham, Alabama

Disclosure: Grant/Research Support: Agios, Amgen, Astellas, Celator, Immunogen, Janssen, Juno, Seattle Genetics, Takeda/Millennium; Consultant: Novartis, Incyte, Celgene, Daiichi Sankyo, Pfizer, Amgen, Sunesis, Janssen, Seattle Genetics, Jazz, Immunogen, Ono; Speaker’s Bureau: Novartis, Incyte, Celgene

Eytan Stein, MD
Assistant Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Advisory Board Member – Celgene Pharmaceuticals

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By